Barclays lowered shares of uniQure (NASDAQ:QURE – Free Report) from an overweight rating to an equal weight rating in a research report sent to investors on Monday morning, Marketbeat Ratings reports. Barclays currently has $28.00 price objective on the biotechnology company’s stock, down from their prior price objective of $60.00.
Several other analysts have also issued reports on QURE. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. The Goldman Sachs Group lowered their price objective on uniQure from $46.00 to $31.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a report on Wednesday, June 17th. Mizuho lifted their price target on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Finally, Weiss Ratings upgraded shares of uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.73.
View Our Latest Stock Report on uniQure
uniQure Stock Performance
uniQure (NASDAQ:QURE – Get Free Report) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million for the quarter, compared to analysts’ expectations of $5.45 million. During the same period in the prior year, the company posted ($0.69) earnings per share. On average, equities research analysts predict that uniQure will post -3.82 EPS for the current year.
Hedge Funds Weigh In On uniQure
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Two Seas Capital LP bought a new position in shares of uniQure during the 3rd quarter valued at about $31,988,000. IFP Advisors Inc lifted its position in shares of uniQure by 39.8% in the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock worth $128,000 after buying an additional 791 shares in the last quarter. Mraz Amerine & Associates Inc. bought a new position in uniQure during the second quarter valued at approximately $390,000. Arizona State Retirement System boosted its stake in uniQure by 17.7% during the second quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company’s stock valued at $596,000 after buying an additional 1,942 shares during the last quarter. Finally, Syon Capital LLC purchased a new position in uniQure during the 2nd quarter valued at approximately $279,000. Institutional investors own 78.83% of the company’s stock.
uniQure Company Profile
uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.
uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.
See Also
- Five stocks we like better than uniQure
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
